Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Moodys
McKesson
Dow

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR TRUVADA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Truvada

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00641641 ↗ The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection Completed Merck Sharp & Dohme Corp. N/A 2008-03-01 The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
New Combination NCT00641641 ↗ The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection Completed Kirby Institute N/A 2008-03-01 The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Truvada

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00074581 ↗ Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed HIV Prevention Trials Network Phase 3 2005-02-01 This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
NCT00074581 ↗ Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2005-02-01 This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
NCT00090779 ↗ Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV Terminated Adult AIDS Clinical Trials Group Phase 2 2005-01-01 Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.
NCT00090779 ↗ Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV Terminated National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2005-01-01 Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.
NCT00090779 ↗ Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV Terminated AIDS Clinical Trials Group Phase 2 2005-01-01 Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.
NCT00105079 ↗ GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Completed Hoffmann-La Roche Phase 3 2005-04-01 This 2 arm study will evaluate the efficacy, safety and tolerability of saquinavir/ritonavir or lopinavir/ritonavir in combination with emtricitabine/tenofovir in patients with human immunodeficiency virus type 1 (HIV-1) infection who have received no prior HIV treatment. Patients will be randomized to receive either saquinavir/ritonavir 1000/100mg oral (po) twice daily (bid) + emtricitabine/tenofovir 200/300mg po once daily (qd), or lopinavir/ritonavir 400/100mg po bid + emtricitabine/tenofovir 200/300mg po qd. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
NCT00110305 ↗ A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines Completed Tibotec Pharmaceuticals, Ireland Phase 2 2005-06-01 The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Truvada

Condition Name

Condition Name for Truvada
Intervention Trials
HIV Infections 80
Hiv 55
HIV Infection 21
HIV Prevention 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Truvada
Intervention Trials
HIV Infections 127
Acquired Immunodeficiency Syndrome 46
Infections 36
Infection 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Truvada

Trials by Country

Trials by Country for Truvada
Location Trials
United States 534
Canada 61
South Africa 57
United Kingdom 40
France 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Truvada
Location Trials
California 52
Florida 34
North Carolina 33
Texas 33
Georgia 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Truvada

Clinical Trial Phase

Clinical Trial Phase for Truvada
Clinical Trial Phase Trials
Phase 4 78
Phase 3 50
Phase 2/Phase 3 8
[disabled in preview] 80
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Truvada
Clinical Trial Phase Trials
Completed 162
Unknown status 15
Recruiting 13
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Truvada

Sponsor Name

Sponsor Name for Truvada
Sponsor Trials
Gilead Sciences 58
Merck Sharp & Dohme Corp. 36
National Institute of Allergy and Infectious Diseases (NIAID) 29
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Truvada
Sponsor Trials
Other 346
Industry 151
NIH 50
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Johnson and Johnson
Medtronic
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.